What is angioimmunoblastic T-cell lymphoma?

Angioimmunoblastic T-cell lymphoma (AITL) is a rare type of blood cancer.

It develops when blood cells called T-cell lymphocytes become abnormal. These blood cells normally help fight infection.

The abnormal T-cells usually build up in the lymph nodes, but they can affect other parts of the body.

AITL is a type of lymphoma called peripheral T-cell lymphoma (PTCL). This is a type of non-Hodgkin lymphoma.

Booklets and resources

Symptoms of AITL

Symptoms often include:

  • feeling generally unwell
  • a rash or itchy skin
  • painless swellings or lumps in the neck, armpit or at the top of the leg (groin). These are caused by the abnormal cells building up in the lymph nodes.

AITL may also affect parts of the body other than the lymph nodes. The symptoms you have will depend on the area affected. You can find out more in our general information about lymphoma symptoms.

B symptoms

AITL may also cause the following 3 symptoms:

  • drenching night sweats
  • unexplained high temperatures
  • unexplained weight loss.

These are called B symptoms. Along with staging and grading (below), B symptoms can help your cancer team understand:

  • how the lymphoma might develop
  • which treatments might help.

Worried about symptoms?

A change in how you feel or how your body works can be caused by conditions other than AITL. But always ask your GP to check any ongoing, new or unexplained symptoms.

We are also here if you need someone to talk to. You can:

Related pages

Causes of AITL

The causes of AITL are mostly unknown. We have more general information about causes and risk factors of non-Hodgkin lymphoma.

AITL mainly affects adults. It usually affects older people, around the age of 70.

Like other cancers, AITL is not infectious. You cannot spread it to other people.

Diagnosis of AITL

AITL often causes symptoms that are linked to other health problems. This sometimes makes diagnosis difficult.

If you have symptoms that worry you, you should begin by going to your GP. They will examine you. If they think cancer may be causing your symptoms, they will refer you to a specialist doctor at a hospital.

The most important test for diagnosing lymphoma is a biopsy. This means testing a small piece of tissue or a sample of cells from an affected area of your body.

Find out more about having a biopsy and other tests in our general lymphoma information.

Waiting for test results

Waiting for test results can be a difficult time. It may take up to 2 weeks for the results to be ready.

You may find it helpful to talk with your partner, your family or a close friend. Your specialist nurse can also provide support.

You can talk to one of our cancer support specialists for free on 0808 808 00 00, 7 days a week, 8am to 8pm.

Booklets and resources

Staging and grading of AITL

Your test results give your cancer team more information about the lymphoma. This includes:

  • The stage

    Staging describes how many areas of the body are affected by lymphoma and where these areas are.

  • The grade

    Grading describes how quickly the lymphoma cells are likely to grow. Burkitt lymphoma is a high grade lymphoma. High grade lymphoma grows more quickly and needs urgent treatment.

Knowing the stage and grade of the lymphoma helps your cancer team plan the right treatment for you.

We have more information about staging and grading non-Hodgkin lymphoma.

Treatment for AITL

A team of specialists will meet to discuss the best possible treatment for you. This is called a multidisciplinary team (MDT).

After the MDT meeting, you will usually meet with your cancer doctor and specialist nurse. They will explain the different treatment options and possible side effects. They will also talk to you about things to consider when making treatment decisions. 

Your treatment options will depend on:

  • the stage of the lymphoma
  • your general health
  • your preferences.

The aim of treatment is to control the lymphoma for as long as possible by making all signs of the lymphoma disappear. This is called remission.

You may have some treatments as part of a clinical trial.

The most treatments are used to treat AITL:

  • Cancer drug treatments

    Treatment for AITL often involves a combination of chemotherapy drugs and steroids. Common combinations include:

    Some people only have steroids to treat AITL. This is usually if they are not well enough to cope with chemotherapy.

    Some people may have other treatments such as targeted therapy drugs as part of a clinical trial.

  • Radiotherapy

    Radiotherapy uses high-energy rays called radiation to treat cancer. It destroys cancer cells in the area you have it.

    Some people have radiotherapy after cancer drug treatment. This can treat any remaining lymphoma cells in the area. It can also reduce the risk of lymphoma coming back in that area.

  • Stem cell transplants

    Stem cell transplants are sometimes used to treat AITL. Stem cell transplants are intensive treatments, so they are not suitable for everyone. They may be used to help keep AITL in remission after cancer drug treatment.

Further treatment

Treatments aim to make all signs of the lymphoma disappear. This is called remission.

Sometimes AITL comes back after treatment. This is called a relapse or recurrence.

If this happens, your cancer team will talk to you about further treatment options. Further treatment is unlikely to cure the lymphoma, but it may help control it for a time.

After AITL treatment

Follow-up after treatment for AITL

You will have regular check-ups during and after your treatment. Your cancer doctor or specialist nurse will explain what to expect.

Follow-up appointments are a good time for you to talk to your cancer doctor or specialist nurse about any concerns you have. Tell them as soon as possible if you have any problems or notice new symptoms between appointments. We have more information about follow-up care after treatment.

Sometimes side effects may continue or develop months or years after treatment. These are called late effects. We have more information about late effects of lymphoma treatment.

Wellbeing and recovery

Looking after yourself can help speed up your recovery after AITL treatment. Even small lifestyle changes may improve your wellbeing and long term health.

Even if you already have a healthy lifestyle, you may choose to make some positive changes after treatment. We have more information on leading a healthy lifestyle after treatment.

Support for people with AITL

People often have many different feelings during and after AITL treatment. If you have finished treatment, you may feel relieved it has ended but worried about what might happen in the future.

It is important to know where to get support or information if you need it. People often need support even some time after AITL treatment. But sometimes it is difficult to know who to ask for help.

You can:

You may also find the HOPE programme helpful. The programme is a free 6 week self-management course designed to help you develop techniques and strategies when living with or after cancer. Topics include goal setting, fatigue management, and wellbeing.

You can sign up for the online HOPE programme. Or to find out more about face to face programmes in your area, email ServiceOpsSupport@macmillan.org.uk

Other organisations who offer information and support

  • Blood Cancer UK offers support and information to people affected by blood cancers, including lymphoma.
  • Lymphoma Action provides high quality information and support for people affected by lymphoma. It provides helpline services and a range of peer support including online support meetings, educational events and webinars. Its website includes TrialsLink, a database of lymphoma clinical trials.

More information and advice

We know cancer can affect you physically, emotionally and financially. We have information and advice about different ways cancer might impact you, such as help with:

About our information

This information has been written, revised and edited by Macmillan Cancer Support’s Cancer Information Development team. It has been reviewed by expert medical and health professionals and people living with cancer.

  • References

    Below is a sample of the sources used in our lymphoma information. If you would like more information about the sources we use, please contact us at informationproductionteam@macmillan.org.uk

     

    Cwynarski K, Marzolini MAV, Barrington SF, et al. The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper. Br J Haematol. 2019;185:402-9.

     

    Eyre TA, Bishton MJ, McCulloch R, et al. Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline. Br J Haematol. 2024;204(1):108–26.

     

    Ferreri AJM, Illerhaus G, Doorduijn K, et al., on behalf of the EHA and ESMO Guidelines Committees. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(6):491-507.

     

    Fox CP, Ahearne MJ, Pettengell R, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. Br J Haematol. 2022;196:507-22.

     

    Fox CP, Chaganti S, McIlroy G, et al. The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline. Br J Haematol. 2024;204(4):1178–92.

     

    McNamara C, Montoto S, Eyre TA, et al. The investigation and management of follicular lymphoma. Br J Haematol. 2020;191:363-81.

     

    Pratt G, El-Sharkawi D, Kothari J, et al. Diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline. Br J Haematol. 2022;197:171–87.

     

    Walewska R, Eyre TA, Barrington S, et al. Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline. Br J Haematol. 2024;204(1):86–107.

Date reviewed

Reviewed: 01 February 2025
|
Next review: 01 February 2028
Trusted Information Creator - Patient Information Forum
Trusted Information Creator - Patient Information Forum

Our cancer information meets the PIF TICK quality mark.

This means it is easy to use, up-to-date and based on the latest evidence. Learn more about how we produce our information.

The language we use


We want everyone affected by cancer to feel our information is written for them.


We want our information to be as clear as possible. To do this, we try to:

  • use plain English
  • explain medical words
  • use short sentences
  • use illustrations to explain text
  • structure the information clearly
  • make sure important points are clear.

We use gender-inclusive language and talk to our readers as ‘you’ so that everyone feels included. Where clinically necessary we use the terms ‘men’ and ‘women’ or ‘male’ and ‘female’. For example, we do so when talking about parts of the body or mentioning statistics or research about who is affected.


You can read more about how we produce our information here.